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cGVHD. 12 pts have relapsed at a median of 128 days (range
76-512) post transplant with a one year actuarial OS of 65%.
Conclusion: This approach permits accurate delivery of a targeted
systemic exposure to IV busulfan, is well-tolerated, and will allow
additional dose escalation. Relapse, as opposed to toxicity, remains
the major challenge.
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TREOSULFAN: AN ATTRACTIVE ALTERNATIVE IN THE CONDITIONING
IN BONE MARROW TRANSPLANT FOR THALASSEMIA
Smiers, F.J.1, Bredius, R.1, Ball, L.1, Lankester, A.1, Bakker, H.2,
Egeler, R.M.1 1Dept Pediatric Hemato Oncology and Bone Marrow
Transplantation, Leiden University Hospital, Leiden, Netherlands;
2Data Management Dept Pediatric Hemato Oncology and Bone Marrow
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Traditionally Busulfan and Cyclofosfamide are used with or
without serotherapy in the conditioning for beta thalassemia. Due
to a high rejection rate in our institution, Melfalan has been added
resulting in a marked reduction of rejection. Toxicity of this reg-
imen is tolerable and consists mainly of mucositis and occasionally
of VOD.
Treosulfan is an alkylating agent with a supposedly lower toxicity
proﬁle than other alkylating agents.
In 12 previously treated thalassemia patients (class 2-3) condi-
tioned with Busulfan, Melfalan, Cyclofosfamide and serotherapy,
mucositis WHO grade 1-2 was seen in 2 patients and grade 3– 4 in
9 patients. VOD was seen in 4 patients and 2 patients had mild
VOD. One patient died due to MOF. Acute GVHD was seen in 6
patients. Chronic GVHD (mild) in 2 patients. Two patients re-
jected but were successfully retransplanted. Ten patients had full
donor chimerism, two patients showed stable mixed chimerism.
In comparison the results in 5 beta thalassemia patients (class 2-3)
conditioned with Treosulfan 10 -14 mg/m2, Cyclofosfamide 120
mg/kg, Melfalan 140 mg/m2 with additional serotherapy (either
ATG or Campath). Two patients had a matched unrelated donor,
3 patients had identical related donors. Three patients received
Treosulfan 10 mg/m2. One patient rejected early and was success-
fully retransplanted with Treosulfan 14 mg/m2. The remaining
two patients received Treosulfan 14 mg/m2. Engraftment was in
normal range. No acute or chronic GVHD was seen. Mucositis
was limited in 3 (WHO grade 2) and moderate to severe (WHO
grade 3-4) in 2 patients. No VOD was seen. Chimerism was stable
mixed in 2 and full donor in three.Conclusion: Treosulfan 14
mg/m2 is well tolerated in thalassemia bone marrow transplant
patients and shows a lower toxicity proﬁle than busulfan.
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IMPACTS OF COMORBIDITIES ON OUTCOMES OF PATIENTS (PTS)
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NANCIES AND TREATED WITH ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT): A MODEL FOR PTS WITH AUTOIMMUNE
DISEASES
Sorror, M.L.1, Storb, R.1,2, Storer, B.1,2, Maloney, D.G.1,2,
Sandmaier, B.M.1,2 1Fred Hutchinson Cancer Research Center; 2Uni-
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The NIH has stated the growing need to explore the therapeutic
and curative potential of allogeneic HCT for autoimmune diseases
(BBMT 2005, 11:862). The safety of HCT in pts with signiﬁcant
comorbidities is of a concern. Here, we analyzed whether the
HCT-CI, a sensitive tool to capture comorbidities (Blood 2005,
106:2912), could assess how young (60 year old) pts with indolent
malignancies tolerated allogeneic HCT strategies as a hypothetical
model for pts with autoimmune diseases. A majority of pts received
myeloablative (MA) conditioning (n364) with cyclophosphamide
plus busulfan (79%) or 12 Gy TBI (21%), while a small group of
pts (n79) received nonmyeloablative (NMA)-conditioning with 2
Gy total body irradiation (18%) 90 mg/m2 of ﬂudarabine (82%).
Diagnoses were acute myeloid leukemia in 1st remission (27%),
chronic myeloid leukemia-chronic phase (40%), myelodysplasia-
refractory anemia (16%), chronic lymphocytic leukemia (8%), low
grade non-Hodgkin lymphoma (4%), and others (5%). At HCT,
NMA-pts differed from MA-pts with respect to age (median 52 vs
41 years,), prior high-dose HCT (9% vs 1%), unrelated grafts
(42% vs 31%), and G-PBMC as stem cell source (87% vs 49%).
HCT-CI scores of 1-2 and 3 were found among 33% and 35%
of NMA vs 35% and 17% of MA-pts, respectively. The most
frequent comorbidities were pulmonary (24%) and hepatic (16%).
After HCT, 4-year cumulative incidences of non-relapse mortality
(NRM) were 10%, 17%, and 36% for MA-pts with HCT-CI
scores of 0, 1-2, and 3, respectively. Proportional hazards mod-
els; adjusted for stem cell source, pt age, donor type, and diagnoses,
were used to estimate hazard ratios (HR) for NRM and survival.
MA-pts with HCT-CI scores of 1-2 or 3 had higher adjusted
HRs for NRM (1.85, p0.06 and 4.56, p0.0001) and all-cause
mortality (2.15, p0.003 and 4.59, p0.0001) compared to pts with
HCT-CI scores of 0. There were no statistically signiﬁcant differ-
ences in NRM between NMA and MA-pts with HCT-CI scores of
0, 1-2, or 3 ( p0.7, p0.1, p0.18, respectively); however, the
small numbers of pts receiving NMA conditioning in each stratum
limited the power of these comparisons. We conclude that among
young pts with indolent malignancies, NRM and survival are
strongly associated with comorbidity after MA-HCT. Therefore,
MA-HCT for treatment of autoimmune diseases might be contra-
indicated for pts with HCT-CI scores of 3. Additional data are
needed to clarify the usefulness of NMA-HCT in indolent dis-
eases.
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OUTCOME OF PATIENTS ACCORDING TO ETHNIC GROUPS RECEIVING
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A total of 106 patients received an allogeneic stem cell transplan-
tation at Kuala Lumpur Hospital between 5/1999 and 5/2006.
Majority received G-CSF stimulated bone marrow as stem cell
source while 20% received PBSC. The race distribution were 52%
Malays, 31% Chinese, 9% Indians and 9% other races. The me-
dian time to neutrophil engraftment was 19 days and platelet
engraftment was 18 days. There was no difference in engraftment
days of platelets and neutrophils between G-CSF stimulated mar-
row and PBSC. The overall survival OS was 61%, event-free
survival EFS was 54% and the 100-day transplant mortality rate
TRM was 16%. The cumulative relapse rate was 24% and the
graft-vs-host disease GVHD rate was 32%.
The overall survival rate according to race was 62% in Malays,
68% in Chinese and 50% in Indians. The cause for mortality in the
Malay race was GVHD at 52%, relapse 29% and infection 29%.
Amongst the Chinese, the major cause for mortality was relapse
60%, GVHD 20% and infection 10%. In the other races, the cause
of mortality was relapse in 70% and GVHD in 20%.
The incidence of moderate Grade II and severe Grade III-IV
acute GVHD was 40% and 29% in the Malays, 43% and 10% in
the Chinese and 22% and 22% in the Indians respectively. Simi-
larly the incidence of limited and extensive chronic GVHD was
12% and 34% in the Malays, 21% and 18% in the Chinese and 0%
and 38% in the Indians.
It is evident that the incidence of severe acute GVHD and
extensive chronic GVHD is higher in the Malays than the other
races. Severe GVHD was also the major cause of mortality
amongst the Malays than the other races. However the rate of
relapse was inversely lower in the Malays than in the Chinese and
Indians.
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